According to a report, the World Health Organization (WHO) advises against the use of the once promising drug Remdesivir for Covid-19 diseases.
After careful examination, a panel of experts from the WHO came to the conclusion that the drug „has no significant influence on mortality or other important effects on patients such as the need for artificial ventilation or the time to recovery,“ wrote the journal British Medical Journal ”in an article published today. It is also not ruled out that the drug could also cause damage. Then there would be the costs.
Remdesivir was originally developed by the US pharmaceutical company Gilead to fight the Ebola virus. After the global pandemic broke out, it was considered a beacon of hope in the fight against Covid-19 for a while. In July, it was the first drug in Europe to receive approval subject to conditions for the specific treatment of certain patients.
Most recently, however, tests had suggested that the drug’s benefit is minimal at best. The findings emerged from a study coordinated by the WHO with thousands of patients in almost 500 clinics in more than 30 countries.
